(S)-2-(2-chloro-5H-chromeno [2,3-b]pyridine-5-yl)-2-methylpropanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (S)-2-(2-chloro-5H-chromeno [2,3-b]pyridine-5-yl)-2-methylpropanoic acid
• 英文别名: (S)-2-(2-chloro-5H-chromeno[2,3-b]-pyridin-5-yl)-2-methylpropanoic acid；(S)-2-(2-chloro-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanoic acid；2-[(5S)-2-chloro-5H-chromeno[2,3-b]pyridin-5-yl]-2-methylpropanoic acid
• 化学式: C₁₆H₁₄ClNO₃
• 分子量: 303.745
• InChiKey: XHFNCORUMWVACV-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-2-(2-chloro-5H-chromeno [2,3-b]pyridine-5-yl)-2-methylpropanoic acid 在 四丁基溴化铵 、 palladium diacetate 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 tricyclohexylphosphine tetrafluoroborate 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 水 为溶剂， 反应 19.5h， 生成 (5S)-2-[4-(dimethylaminocarbonyl)-3-fluorophenyl]-α,α-dimethyl-N-(1,3,4-thiadiazol-2-yl)-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide
  参考文献：
  名称：

  实用合成的功能化氮杂蒽酮衍生的非甾体糖皮质激素受体调节剂的开发。

  摘要：

  报道了一种有效的途径来制备两个官能化的2-芳基-5 H -chromeno [2,3- b ]吡啶（金刚烷类）。向水杨醛中添加锂化的2,6-二氯吡啶，然后环化是确定形成氮杂黄嘌呤核的关键工艺改进。2-氯-5-的进一步阐述ħ -chromeno [2,3- b ]吡啶-5-醇在5位被通过与市售的（（1-甲氧基-2-甲基丙-1-路易斯酸催化的偶联来完成烯-1-基）氧基）三甲基硅烷。使用部分经典拆分方法与制备型手性超临界流体色谱法（SFC）分离来分离所需的氮杂蒽吨羧酸的对映异构体，该杂合体是两种化合物的共同中间体1和2。Suzuki-Miyaura与适当取代的硼酸交叉偶联，然后与2-氨基-1,3,4-噻二唑缩合，可提供目标化合物的总收率约为10％。还讨论了使用稳定的无定形材料来支持功能性氮杂黄嘌呤1和2的临床比较。

  DOI：

  10.1021/acs.oprd.6b00035
• 作为产物：
  描述：

  5H-[1]-苯并吡喃o[2,3-b]吡啶-5-醇 在 四氯化钛 、 间氯过氧苯甲酸 、 potassium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 13.67h， 生成 (S)-2-(2-chloro-5H-chromeno [2,3-b]pyridine-5-yl)-2-methylpropanoic acid 、 (R)-2-(2-chloro-5H-chromeno[2,3-b]-pyridin-5-yl)-2-methylpropanoic acid
  参考文献：
  名称：

  Azaxanthene Based Selective Glucocorticoid Receptor Modulators: Design, Synthesis, and Pharmacological Evaluation of (S)-4-(5-(1-((1,3,4-Thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and Its Methylene Homologue (BMS-791826)

  摘要：

  Structurally novel 5H-chromeno[2,3-b]pyridine (azaxanthene) selective glucocorticoid receptor (GR) modulators have been identified. A screening paradigm utilizing cellular assays of GR-mediated transrepression of proinflammatory transcription factors and transactivation of GR-dependent genes combined with three physiologically relevant assays of cytokine induction in human whole blood has allowed for the identification of high affinity, selective GR ligands that display a broad range of pharmacological profiles. Agonist efficacy in reporter assays can be tuned by halogenation of a pendent phenyl ring and correlates well with efficacy for cytokine inhibition in human whole blood. A hypothetical binding mode is proposed, invoking an expanded ligand binding pocket resembling that of arylpyrazole-bound GR structures. Two compounds of dose structural similarity (35 and 37; BMS-776532 and BMS-791826, respectively) have been found to maintain distinct and consistent levels of partial agonist efficacy across several assays, displaying anti-inflammatory activity comparable to that of prednisolone 2 in suppressing cytokine production in whole blood and in rodent models of acute and chronic inflammation.

  DOI：

  10.1021/jm200879j

文献信息

• [EN] IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR<br/>[FR] DÉRIVÉS IMIDE ET ACYLURÉE UTILISÉS COMME MODULATEURS DU RÉCEPTEUR DE GLUCOCORTICOÏDES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015027021A1

  公开（公告）日：2015-02-26

  Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-KB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.

  提供了一种新型的非类固醇化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-KB活性调节相关的疾病或紊乱，包括代谢性、炎症性和免疫性疾病或紊乱，其结构如下式（I）：其对映体、二对映体或互变异构体，或其药用可接受盐，其中变量如规范中所定义。
• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Weinstein David S.

  公开号：US20090075995A1

  公开（公告）日：2009-03-19

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R 5 , R 6 , R 7 , and R 8 ; J 1 , J 2 , and J 3 are at each occurrence the same or different and are independently -A 1 QA 2 -; Q is a bond, O, S, S(O), or S(O) 2 ; A 1 and A 2 are the same or different and are at each occurrence independently selected from a bond, C 1-3 alkylene, substituted C 1-3 alkylene, C 2-4 alkenylene, and substituted C 2-4 alkenylene, provided that A 1 and A 2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R 1 to R 11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了一系列新颖的非甾体化合物，这些化合物在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病中很有用，包括炎性和免疫疾病，具有以下结构式（I）： 其对应的光学异构体、对映异构体或互变异构体，或其前药酯，或其药用可接受盐，其中： Z是杂环或杂芳基； A是一个5至8成员的碳环或一个5至8成员的杂环； B是一个环烷基、环烯基、芳基、杂环或杂芳基环，其中每个环都与A环上的相邻原子融合，并且可以选择性地被一个到四个独立选自R5、R6、R7和R8的相同或不同的组取代； J1、J2和J3每次出现时相同或不同，独立地选自-A1QA2-；Q是键、O、S、S(O)或S(O)2；A1和A2相同或不同，每次出现时独立地选自键、C1-3烷基、取代的C1-3烷基、C2-4烯基和取代的C2-4烯基，前提是A1和A2的选择使得环A是一个5至8成员的碳环或杂环； R1至R11如本文所述定义。 还提供了使用这些化合物的药物组合物和治疗炎性疾病、免疫相关疾病、肥胖和糖尿病的方法。
• Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
  申请人：Bristol-Myers Squibb Company

  公开号：US08034940B2

  公开（公告）日：2011-10-11

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R5, R6, R7, and R8; J1, J2, and J3 are at each occurrence the same or different and are independently -A1QA2-; Q is a bond, O, S, S(O), or S(O)2; A1 and A2 are the same or different and are at each occurrence independently selected from a bond, C1-3alkylene, substituted C1-3alkylene, C2-4alkenylene, and substituted C2-4alkenylene, provided that A1 and A2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R1 to R11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

  提供了新型非甾体化合物，其在治疗与葡萄糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病方面具有用途，包括炎症和免疫疾病，其具有以下结构（I）的构造： 其中，Z是杂环或杂环芳基；A是5-至8-成员的碳环或5-至8-成员的杂环；B是环烷基，环烯基，芳基，杂环芳基或杂环，其中每个环在相邻原子上与A环融合，并且可选地被一个到四个相同或不同的基团取代，这些基团是独立地从R5、R6、R7和R8中选择的；J1、J2和J3在每次出现时相同或不同，并且独立地是-A1QA2-；Q是键，O，S，S（O）或S（O）2；A1和A2在每次出现时相同或不同，并且独立地从键，C1-3烷基，取代的C1-3烷基，C2-4烯基和取代的C2-4烯基中选择，前提是A1和A2被选择为环A是5-至8-成员的碳环或杂环；R1到R11如本文所定义。 还提供了制药组合物和使用所述化合物治疗炎症或免疫相关疾病以及肥胖症和糖尿病的方法。
• Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists
  作者：Hua Gong、Michael Yang、Zili Xiao、Arthur M. Doweyko、Mark Cunningham、Jinhong Wang、Sium Habte、Deborah Holloway、Christine Burke、David Shuster、Ling Gao、Julie Carman、John E. Somerville、Steven G. Nadler、Luisa Salter-Cid、Joel C. Barrish、David S. Weinstein

  DOI：10.1016/j.bmcl.2014.06.010

  日期：2014.8

  Acylureas and acyclic imides are found to be excellent isosteres for 2-acylamino-1,3,4-thiadiazole in the azaxanthene-based series of glucocorticoid receptor (GR) agonists. The results reported herein show that primary acylureas maintain high affinity and selectivity for GR while providing improved CYP450 inhibition and pharmacokinetic profile over 2-acylamino-1,3,4-thiadiazoles. General methods for synthesis of a variety of acylureas and acyclic imides from a carboxylic acid were utilized and are described. (C) 2014 Elsevier Ltd. All rights reserved.
• Improving the Pharmacokinetic and CYP Inhibition Profiles of Azaxanthene-Based Glucocorticoid Receptor Modulators—Identification of (<i>S</i>)-5-(2-(9-Fluoro-2-(4-(2-hydroxypropan-2-yl)phenyl)-5<i>H</i>-chromeno[2,3-<i>b</i>]pyridin-5-yl)-2-methylpropanamido)-<i>N</i>-(tetrahydro-2<i>H</i>-pyran-4-yl)-1,3,4-thiadiazole-2-carboxamide (BMS-341)
  作者：Michael G. Yang、T. G. Murali Dhar、Zili Xiao、Hai-Yun Xiao、James J.-W. Duan、Bin Jiang、Michael A. Galella、Mark Cunningham、Jinhong Wang、Sium Habte、David Shuster、Kim W. McIntyre、Julie Carman、Deborah A. Holloway、John E. Somerville、Steven G. Nadler、Luisa Salter-Cid、Joel C. Barrish、David S. Weinstein

  DOI：10.1021/acs.jmedchem.5b00257

  日期：2015.5.28

  An empirical approach to improve the microsomal stability and CYP inhibition profile of lead compounds 1a and 1b led to the identification of 5 (BMS-341) as a dissociated glucocorticoid receptor modulator. Compound 5 showed significant improvements in pharmacokinetic properties and, unlike compounds 1a-b, displayed a linear, dose-dependent pharmacokinetic profile in rats. When tested in a chronic model of adjuvant-induced arthritis in rat, the ED50 of 5 (0.9 mg/kg) was superior to that of both 1a and 1b (8 and 17 mg/kg, respectively).